Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

WARSAW, Ind., Aug. 31, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at Baird's 2021 Virtual Global Healthcare Conference on Tuesday, September 14, 2021, at 10:50 a.m.

Zimmer Biomet to Present at Baird's 2021 Virtual Global Healthcare Conference

WARSAW, Ind. and VANCOUVER, BC, Aug. 30, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Canary Medical, a medical data company, today announced U.S. Food and Drug Administration (FDA) De Novo classification grant and authorization to market the tibial extension for Persona IQ®, the world's first and only smart knee cleared by the FDA for total knee replacement surgery.

Zimmer Biomet and Canary Medical Announce FDA De Novo Classification Grant and Authorization to Market the World's First and Only Smart Knee Implant

The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.

Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System

Zimmer Biomet Holdings Inc (NYSE: ZBH) has received FDA 510(k) clearance for its Rosa Hip system for robotically-assisted surgery. The system is designed for direct anterior total hip replacement.

FDA Approves Zimmer Biomet's Rosa Hip Personalized Robotic System

WARSAW, Ind., Aug. 18, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Hip System for robotically-assisted direct anterior total hip replacement.

Zimmer Biomet Receives FDA Clearance for ROSA® Hip System for Robotically-Assisted Direct Anterior Total Hip Arthroplasty

WARSAW, Ind., Aug. 17, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced six data presentations at the American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting scheduled to be held on August 31 to September 3 in San Diego.

Zimmer Biomet to Unveil New Clinical Data and Portfolio of Innovative Technologies at AAOS 2021 Annual Meeting

Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.

Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic

The stock price of Zimmer Biomet Holdings, a medical devices company, reached its all-time high of $178 in April this year, but it has since seen lower levels. A recent sell-off in the stock has led to over a 9% drop in its price over the last five trading days to levels of $148 currently.

Will Zimmer Biomet Holdings Stock Rebound After A 9% Fall In A Week

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q2 2021 Results - Earnings Call Transcript

Zimmer Biomet Holdings Inc (NYSE: ZBH) posted Q2 adjusted EPS of $1.90, ahead of the consensus of $1.87 and higher than $0.05 posted a year ago. It reported a profit of $142.5 million, upping its bottom line from a loss of $(208.60) million in Q2 of 2020.

Zimmer Biomet Stock Falls After Lowering Bottom End Of FY21 Outlook; Q2 Earnings Beat

Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand

Zimmer (ZBH) delivered earnings and revenue surprises of 3.26% and 2.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q2 Earnings and Revenues Surpass Estimates

Shares of Zimmer Biomet Holdings (NYSE:ZBH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 3700.00% over the past year to $1.90, which beat the estimate of $1.87.

Recap: Zimmer Biomet Q2 Earnings

WARSAW, Ind., Aug. 3, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2021.

Zimmer Biomet Announces Second Quarter 2021 Financial Results

Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Earnings Expected to Grow: Should You Buy?

Zimmer Biomet presents as a compelling investment case particularly with a contrarian flavour to one's thinking.

Zimmer Biomet: Key Inflection Points For Consideration

WARSAW, Ind., July 6, 2021 /PRNewswire/ -- Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 3, 2021 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2021 Financial Results

WARSAW, Ind., June 10, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2021.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2021

Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival

WARSAW, Ind., June 7, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced two new appointments to the Company's Executive Leadership Team.

Zimmer Biomet Announces New Appointments to Executive Leadership Team

Johnson & Johnson

Stryker

As hospitals address the major backlog of pandemic-postponed elective surgeries, medical device makers -- and their stock prices -- could benefit.

This Part of the Reopening Trade Is Just Getting Started

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Zimmer (ZBH) Down 7.2% Since Last Earnings Report: Can It Rebound?

Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.

Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now

WARSAW, Ind., May 25, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, at 11:20 a.m.

News for Zimmer Biomet Hlds Stock (ZBH)